Erudio Healtherudio.com
Clinical trial · no report yet · Phase 1
INDUCE-1
Dose Escalation and Expansion Study of GSK3359609 in Participants With Selected Advanced Solid Tumors (INDUCE-1)
- NCT02723955 ↗
- Completed
- GlaxoSmithKline
- Focused
We haven't built an HCP commentary report on INDUCE-1 yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on INDUCE-1 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 2 | |
| YouTube | 1 |
The trial
ClinicalTrials.gov- Official title
- A Phase I Open Label Study of GSK3359609 Administered Alone and in Combination With Anticancer Agents in Subjects With Selected Advanced Solid Tumors
- Phase
- Phase 1
- Status
- Completed
- Conditions
- Neoplasms
- Interventions
- feladilimab (GSK3359609); GSK3174998; Pembrolizumab; Docetaxel; Pemetrexed; Paclitaxel plus Carboplatin; Gemcitabine plus Carboplatin; Fluorouracil (5-FU) plus carboplatin or cisplatin; Dostarlimab; Cobolimab; Bintrafusp alfa
- Arms
- Part 1A: Dose escalation feladilimab (GSK3359609) · Experimental
- Part 1B: Expansion feladilimab (GSK3359609) · Experimental
- Part 2A: Dose escalation (feladilimab (GSK3359609)+pembrolizumab) · Experimental
- Part 2A: Dose escalation (feladilimab (GSK3359609)+GSK3174998) · Experimental
- Part 2A: Safety run-in (feladilimab (GSK3359609)+chemotherapy) · Experimental
- Part 2B: Expansion-feladilimab (GSK3359609) · Experimental
- Part 2A: Dose escalation (feladilimab (GSK3359609)+ dostarlimab) · Experimental
- Part 2A: Dose escalation (feladilimab (GSK3359609)+dostarlimab+cobolimab) · Experimental
- Part 2A: Dose escalation (feladilimab (GSK3359609)+bintrafusp alfa) · Experimental
- Enrollment
- 829
- Primary outcomes
- Part 1A: Number of Participants With Any Adverse Event(s) (AEs) and Serious Adverse Event(s) (SAEs)
- Part 1A: Number of Participants With Dose Limiting Toxicity (DLT)
- Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters
- Part 1A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline
- Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters
- Part 1A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline
- Part 1A: Number of Participants With Worst Case Urinalysis Results Post-Baseline Relative to Baseline
- Part 1A: Number of Participants With Dose Modifications of Feladilimab
- Part 2A: Number of Participants With Any Adverse Event(s) (AEs) and Serious Adverse Event(s) (SAEs)
- Part 2A: Number of Participants With Dose Limiting Toxicity (DLT)
- Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters
- Part 2A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline
- Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters
- Part 2A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline
- Part 2A: Number of Participants With Worst Case Urinalysis Results Post-Baseline Relative to Baseline
- Part 2A: Number of Participants With Dose Modifications of Feladilimab
- Sponsor
- GlaxoSmithKline with Merck Sharp & Dohme LLC
- Start
- Jun 23, 2016
- Primary completion
- Jul 5, 2023
- Results posted
- Yes
- Registry record
- NCT02723955 · updated Dec 27, 2024
Publications
linked from the registry- Turner DC, Wada R, Zhou H, Wang X, de Greef R, Valiathan C, Zhang L, Zhang N, Kuchimanchi M, Chen TT, Ballas M, Visser SAG. Model-based meta-analysis of non-small cell lung cancer with standard of care PD-1 inhibitors and chemotherapy for early development decision making. CPT Pharmacometrics Syst Pharmacol. 2023 Nov;12(11):1751-1763. doi: 10.1002/psp4.12917. Epub 2023 Jan 31. PubMed 36642813
- Yadavilli S, Waight JD, Brett S, Bi M, Zhang T, Liu YB, Ellis C, Turner DC, Hahn A, Shi H, Seestaller-Wehr L, Jing J, Xie Q, Shaik JS, Ji X, Gagnon R, Fieles W, Hook L, Grant S, Hopley S, DeYoung MP, Blackwell C, Chisamore M, Biddlecombe R, Figueroa DJ, Hopson CB, Srinivasan R, Smothers J, Maio M, Rischin D, Olive D, Paul E, Mayes PA, Hoos A, Ballas M. Activating Inducible T-cell Costimulator Yields Antitumor Activity Alone and in Combination with Anti-PD-1 Checkpoint Blockade. Cancer Res Commun. 2023 Aug 16;3(8):1564-1579. doi: 10.1158/2767-9764.CRC-22-0293. eCollection 2023 Aug. PubMed 37593752